Released on = January 31, 2006, 11:00 pm

Press Release Author = Bagolie Friedman Injury Lawyers

Industry = Consumer Services

Press Release Summary = The New Jersey, USA Offices of Bagolie Friedman Injury
Lawyers are investigating overdose deaths linked to the fentanyl pain patch. Known
as the Duragesic Trans dermal Patch, it is a device developed to alleviate chronic
pain which could possibly leak, exposing patients to dangerous levels of fentanyl, a
powerful opiate based pain reliever.

Press Release Body = For Immediate Release:
2/1/06


Jersey City, New Jersey February 2006 - The New Jersey, USA Offices of Bagolie
Friedman Injury Lawyers are investigating overdose deaths linked to the fentanyl
pain patch. Known as the Duragesic Transdermal Patch, it is a device developed to
alleviate chronic pain which could possibly leak, exposing patients to dangerous
levels of fentanyl, a powerful opiate based pain reliever.

The fentanyl patch is comprised of an outer impermeable plastic shell and a drug
permeable inner lining. The patch is applied directly to the skin where heat from
the body activates a regular release of fentanyl over a 72 hour period. This drug is
a powerful opiate pain-reliever held in a gel suspension between the two linings of
the patch. The inner lining only lets a certain amount of the drug into the body
based on the needs of the patient, typically between 25 to 100 micrograms per hour.
Sales of Duragesic earned Janssen Pharmaceutica over a billion dollars between the
year 2002-2003. Unfortunately a problem in the seal between the linings was
discovered in February 2004, prompting Janssen to initially recall one group of the
patches, but an additional four groups of the patch were removed from the market
later in April. The company has since recalled over two million of the patches.

Bagolie Friedman Injury Lawyers, with affiliate offices in Jersey City and Clifton
New Jersey, Hollywood Florida and Brisbane, Australia, have begun to review and
accept injury cases from surviving family members and individuals who have suffered
from Fentanyl overdose. \"We will be reviewing potential cases from the United
States, Australia and Europe,\" said founding partner, Ricky Bagolie.

Duragesic is no longer the only fentanyl pain patch being marketed. On January 28,
2005, the U.S. Food and Drug Administration (FDA) granted final approval for Mylan
Laboratories, Inc. to market a generic fentanyl transdermal system. The manufacturer
of Duragesic® has also begun to market an authorized generic version of the fentanyl
patch through an agreement with Sandoz. Other generic companies have applications
pending at the FDA to market similar fentanyl patches, therefore, other generic
versions may soon be available. Problems associated with these newer generic patches
have also been reported. \"It is very difficult for a person examining a fentanyl
patch to detect a defect or leak. This can lead to a dangerous situation as exposure
to an excessive amount of fentanyl can lead to serious injury or death.\" says
attorney Alan Friedman.

If you believe that you, or a member of your family, has been injured or suffered
from an overdose as a result of receiving a fentanyl pain , contact Ricky Bagolie or
Alan Friedman toll free at 1-866-333-3529, e-mail them at info@bagoliefriedman.com
or visit http://www.bagoliefriedman.com now for a confidential and free
consultation.

###

For more information contact:
Ricky Bagolie
http://bagoliefriedman.com
info@bagoliefriedman.com


Web Site = http://bagoliefriedman.com

Contact Details = Ricky Bagolie